Fresh from raising $200M, British biotech with an HQ in Raleigh mulls targeting COVID-19
A British clinical-stage biotech firm with U.S. headquarters in Raleigh is exploring the option of repurposing its leading drug candidate to treat COVID-19 patients. Here’s what’s happening.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
